Hang on a minute - we have not cured TBI - but there are no bad side effects and "Superiority of drug over placebo was demonstrated in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), which was one of the exploratory efficacy measures in the INTREPID trial. RBANS is a validated series of tests completed by the patient for assessing cognitive impairment that is commonly used in the diagnosis and tracking of dementia. RBANS has also been validated for use in moderate-to-severe TBI."
So - people with TBI do not necessary not die if they use Trofinetide but their quality of life improves. Isn't that a good thing?
- Forums
- ASX - By Stock
- NEU
- Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX
Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX, page-5
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B |
Open | High | Low | Value | Volume |
$14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $13.99 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.07 | 6644 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 13.990 |
1 | 300 | 13.970 |
1 | 1432 | 13.950 |
2 | 1230 | 13.900 |
1 | 720 | 13.890 |
Price($) | Vol. | No. |
---|---|---|
14.420 | 175 | 1 |
14.500 | 2985 | 2 |
14.800 | 2850 | 2 |
14.860 | 500 | 1 |
14.960 | 445 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
NEU (ASX) Chart |